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Spontaneous aggregation of Ab is a key factor in the development of Alzheimer’s disease. In search-
ing for Ab aggregation inhibitors from traditional Chinese herbal medicines, we identiﬁed two active
compounds from Psoraleae Fructus, namely isobavachalcone and bavachinin. We further demon-
strated that the two compounds modulate Ab42 aggregation process through different mechanisms.
Isobavachalcone signiﬁcantly inhibits both oligomerization and ﬁbrillization of Ab42, whereas bav-
achinin inhibits ﬁbrillization and leads to off-pathway aggregation. Both of the compounds attenu-
ated Ab42-induced toxicity in a SH-SY5Y cell model. These ﬁndings may provide valuable
information for new drug development and Alzheimer’s therapy in the future.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by extracellular amyloid plaques and
intraneuronal ﬁbrillary tangles in the brain [1]. Abnormal accumu-
lation and aggregation of the amyloid b (Ab) peptides, especially
the peptides with 40 (Ab40) or 42 residues (Ab42), are believed
to be responsible for the amyloid plaques [2]. Oligomerization
and ﬁbrillization of Ab peptide, especially Ab42, is the key event
leading to development of AD plaques as well as progressive neu-
ronal loss. Inhibition of aggregation of Ab peptide is a potential
therapeutic approach for the treatment of AD [3–5]. Varieties of
Ab aggregation inhibitors have been discovered, including natural
products from plants, for example, the plant phenolic compoundsthat show strong inhibitory effect on Ab aggregation both in vitro
and in vivo [6,7].
Psoraleae Fructus, the dried fruits of Psoralea corylifolia L., is a
yang-tonifying herb commonly used in clinical practices of Tradi-
tional Chinese Medicine (TCM). Recent studies have shown that
it possesses multiple beneﬁts, including anti-bacteria [8], anti-oxi-
dant [9], anti-tumor [10,11], immune-modulation [11], estrogenic
and bone-strengthening, etc. [12–14]. Chemical composition of
Psoraleae Fructus is also well studied. It mainly contains coumarins
and prenylﬂavone derivatives [15–18]. Choi et al., recently re-
ported that the compounds from Psoraleae Fructus strongly inhibit
BACE1 (b-secretase) activity [19], a key enzyme in Ab production
in vivo. However, the effect of these compounds on Ab aggregation
remains unclear.
Recently we established a yeast two-hybrid system to screen
the inhibitors of Ab42 aggregation [20]. In a screening of tradi-
tional Chinese herbal medicines, we found the methanol extract
of Psoraleae Fructus showed strong inhibitory effect on Ab42
aggregation. In this study, we further conﬁrmed the anti-aggrega-
tion effect of Psoraleae Fructus and demonstrated isobavachalcone
and bavachinin as the major active compounds effectively inhib-
iting the on-pathway aggregation of Ab42 through two different
mechanisms.
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2.1. Reagents and chemicals
Ab42 (purity >95%) was synthesized by ChinaPeptides (Shang-
hai, China). Thioﬂavin T (ThT) and hexaﬂuoroisopropanol (HFIP)
were obtained from Sigma (St. Louis, USA). EGCG, curcumin, psor-
alen, isopsoralen, psoralidin, bavachin, bavachinin, bakuchiol,
neobavaisoﬂavone, and isobavachalcone were purchased from
Shanghai Yuanye Bio-Technology Co. (Shanghai, China). All of
chemical compounds were dissolved in DMSO for Ab42 inhibition
assay, or in methanol for CD Spectroscopy analysis. Compound
structures are shown in Fig. 1.
2.2. Plant materials and extracts
Psoraleae Fructus was purchased from a local TCM drug store
and identiﬁed as the dried fruits of Psoralea corylifolia L. The herb
sample was grinded into ﬁne powder. Five grams of the powder
was extracted twice with 50 ml methanol by 30 min ultra-sonica-
tion and 5 min reﬂuxation in a microwave extractor. The methanol
extracts were ﬁltered, vacuum-dried at 40 C, then stored at
30 C. For Ab42 inhibition assay, fresh samples dissolved in
DMSO were used without frozen storage.
2.3. HPLC analysis and quantiﬁcation of the extracts
HPLC analysis was performed on an Agilent 1260 Inﬁnity LC
system with a DAD detector and an Alltima C18 column (Alltech,
4.6  250 mm, 5 lm). Separation was conducted at 25 C with a
binary mobile phase consisting of 0.1% aqueous acetic acid (solvent
A) and acetonitrile (solvent B) at a ﬂow rate of 1.0 ml/min [18]. A
gradient elution program was applied as follows: 40–50% B in
15 min, 50–60% B in 20 min, 60–80% B in 20 min, and 80% B for
5 min. Elution peaks were detected at wavelength 245 nm. Psora-
len, isopsoralen, psoralidin, bavachin, bavachinin, bakuchiol, neob-
avaisoﬂavone, and isobavachalcone were used as reference
standards for quantiﬁcation.
2.4. Yeast two-hybrid inhibition assay
A yeast two-hybrid system for screening Ab42 inhibitors has
been described previously [20]. Brieﬂy, the transformed yeast
strain AH109 (Clontech) carries two Ab42-fusion plasmids (Ab42Fig. 1. Representative HPLC chromatograph of the methanol extract of Psoraleae Fructus a
the eight standards are shown at the top.fused to GAL4-DB of pGBKT7 and GAL4-AD of pGADT7) which
was maintained on the high-stringency SD4 media (synthetic
media depleted of leucine, tryptophan, adenine and histidine).
The fresh yeast clone was inoculated into SD4 liquid media, grown
and harvested in early log-phase (OD600 = 0.5–1.0), and diluted to
OD600 = 0.1. The yeast cells were aliquoted and grown at 30 C for
48 h in the presence or absence of the test compounds. The reduc-
tion in growth rate of each compound was calculated according to
DMSO (vehicle) control and used as an index for Ab42 inhibition.
2.5. Inhibition of Ab42 aggregation
Synthetic Ab42 peptide was prepared as described previously
with minor modiﬁcations [21]. Ab42 was ﬁrst dissolved in 100%
HFIP and dried under nitrogen gas. The dried peptide was reconsti-
tuted in DMSO (or 10 mM NaOH for CD spectroscopy, 5 mg/ml
Ab42), then sonicated for 10 min, and diluted in PBS (pH 7.4) to
50 lM. The peptide was centrifuged at18000g for 60 min at
25 C. The supernatant was aliquoted and incubated at 37 C in
the presence or absence of compounds for 0–7 days without
agitation.
2.6. ThT ﬂuorescence assay
Ab42 samples (10 ll) were mixed with 40 ll ThT solutions
(25 lM in 0.2 M Glycine–NaOH buffer, pH 8.5), placed in the dark
for 10 min, and then measured at 440/490 nm (excitation/emis-
sion) in a ﬂuorescence spectrophotometer (F96Pro, Shanghai Leng-
guang Technology Co. Ltd., China). To pellet the aggregates, Ab42
samples were centrifuged at 18000g for 30 min at 25 C and
the pelleted fraction (5% of starting volume) was analyzed by
ThT ﬂuorescence assay.
2.7. SDS–PAGE
Ab42 samples were mixed with loading buffer, and separated in
a 15% Tris–glycine PAGE gel at 60 V. Gels were then stained by Coo-
massie Blue [22].
2.8. Dot blot assay
Two conformation-speciﬁc antibodies were applied for dot blot
assay to detect formation of Ab42 oligomers (A11, Invitrogen) and
ﬁbrils (OC, Millipore) as described previously [21]. Brieﬂy, Ab42nd quantiﬁcation of the major constituents. The chemical structures and contents of
Fig. 2. Effect of PFE and its major compounds on Ab42 aggregation. (A) Yeast two-
hybrid analysis. Yeasts were grown in SD4 medium for 48 h with the test
substances adding at non-toxic concentrations (PFE: 10 lg/ml; NBIF and IBC: 3 lM;
other compounds: 30 lM). Curcumin was used as a positive control (Cur, 150 lM).
(B) ThT ﬂuorescence assay. Ab42 (50 lM) were incubated with PFE (100 lg/ml) or
test compounds (50 lM) for 1 day. EGCG (50 lM) was used as a positive control.
DMSO was served as a vehicle control for both assay (n = 3).
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dried. The membranes were blocked 2 h at room temperature with
10% non-fat milk in Tris–buffered saline containing 0.01% Tween
20 (TBST). The membranes were then washed and probed with
either oligomer-speciﬁc A11 or ﬁbril-speciﬁc OC overnight at
4 C, which was diluted 1:1000 in TBST containing 5% milk. The
membranes were washed again and incubated with anti-rabbit
horseradish peroxidase-conjugated secondary antibodies diluted
1:5000 in TBS-T containing 5% milk for 2 h at room temperature.
Then the blots were washed three times with TBS-T for 5 min
and developed with the ECL chemiluminescence kit (SuperSignal
West Pico, Thermo Fisher Scientiﬁc Inc.).
2.9. Circular dichroism spectroscopy (CD)
The CD spectra of Ab42 samples were measured by a Jasco J-810
CD spectrometer at 25 C. Each spectrum is the average of at least 5
readings.
2.10. Atomic force microscopy (AFM)
Ab42 samples were diluted 1:4 in PBS (pH 7.4) and spotted on
freshly cleaved mica. The samples were adsorbed 30 min at room
temperature and then washed three times with water and dried
overnight. Images were taken at DFM mode using a Seiko SPA
400 AFM system with Tap300Al cantilevers (BudgetSensors).
2.11. Ab42 induced cell toxicity
MTT assay was performed to determine the cell toxic effects of
Ab42 samples in SH-SY5Y human neuroblastoma cells. The cells
were seeded at a concentration of 4000 cells/well (200 ll/well) in
96-well plates in full medium (DMEM/F12) and incubated 48 h at
37 C. The medium was replaced with 100 ll of serum-free med-ium containing 10% Ab42 aggregation samples. The cells were trea-
ted for 48 h at 37 C before MTT was added to each well (0.5 mg/
ml, ﬁnal concentration) and incubated for 4 h at 37 C. The culture
solution was removed and 150 ll of DMSO was added. The plates
were shaken for 10 min and measured at 492 nm using a micro-
plate reader.3. Results
3.1. The major constituents in the methanol extract of Psoraleae
Fructus
HPLC analysis of the methanol extract of Psoraleae Fructus (PFE)
showed that peaks of the major constituents were well resolved.
Eight compounds were quantiﬁed using reference standards
(Fig. 1). Bakuchiol is the most abundant (BKC, 44.59%), followed
by psoralidin (PLD, 5.5%), bavachinin (BCN, 2.16%), isobavachal-
cone (IBC, 1.61%), neobavaisoﬂavone (NBIF, 1.48%), bavachin (BC,
1.14%), isopsoralen (IPL, 1.12%) and psoralen (PL, 0.91%). This is
consistent with previous reports [16,17].
3.2. PFE and the compounds IBC, BCN inhibit Ab42 dimerization in
yeast two-hybrid model
An established yeast two-hybrid system was ﬁrst applied to
investigate the inhibitory effect of PFE and the eight compounds
on Ab42 self interaction. The yeast model is based on the hetero-
dimerization of Ab42-fusion protein, which reconstituted GAL4
transcriptor to drive its downstream reporter genes compensating
for the multiple auxotrophic phenotype of the yeast strain [20].
Therefore, the yeast growth in high-stringency SD4media is com-
pletely dependent on Ab42 self interaction thus was used as a read
out for evaluation of Ab42 inhibitors. Toxicity dependent false-po-
sitive effects were identiﬁed by a parallel test replacing SD4 with
complete SD media. As shown in Fig. 2A, PFE (10 lg/ml) and curcu-
min (150 lM), a known inhibitor, signiﬁcantly reduced the yeast
growth in SD4 medium, indicating that they strongly inhibit
Ab42 dimerization. Among the eight test compounds, IBC (3 lM)
and BCN (30 lM) were found to be active at non-toxic
concentrations.
3.3. PFE and the compounds IBC, BCN inhibit formation of Ab42
ﬁbrillar aggregates in vitro
To further conﬁrm whether PFE and the compounds can inhibit
Ab42 aggregation, a standard ThT ﬂuorescence assay was per-
formed. ThT is known to speciﬁcally bind to Ab42 ﬁbrillar conform-
ers and generate a unique ﬂuorescence spectrum peaking near
490 nm. As shown in Fig. 2B, both the positive control EGCG and
PFE signiﬁcantly reduced ThT ﬂuorescence, indicating they inhib-
ited formation of Ab42 ﬁbrillar aggregates. IBC also exhibited
strong inhibitory effect on ThT ﬂuorescence, which is comparable
with EGCG. Interestingly, while BCN only showed mild reduction
on yeast growth, it decreased ThT ﬂuorescence more efﬁciently.
We further determined the IC50 of IBC and BCN in the ThT assay
and they are about 25 and 45 lM, respectively.
3.4. IBC inhibits formation of high molecular weight aggregates of
Ab42 whereas BCN promotes conversion of low molecular weight
conformers
To explore how IBC and BCN modulate Ab42 aggregation, SDS–
PAGE analysis was carried out. Two major bands corresponding to
monomers and low molecular weight conformers (trimers/tetra-
mers) were observed in Ab42 samples before incubation
Fig. 4. Dot blotting analysis using OC and A11 antibodies. Ab42 samples (50 lM)
were incubated for 0–7 days with IBC or BCN (1, 2, 5: a molar ratio of 1:1, 2:1,
5:1 to Ab42). Each image is a representative of at least three independent
experiments.
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markedly accumulated in the samples. Addition of IBC greatly pre-
vented the formation of high molecular weight aggregates, further
conﬁrmed its anti-aggregation effect (Fig. 3A and B). Interestingly,
BCN treatment led to no signiﬁcant effect on high molecular
weight aggregates but noticeably reduced low molecular weight
conformers. This result suggests that IBC and BCN modulate
Ab42 aggregation in two different manners. PFE treatment pro-
duced an intermediate effect compared with the two compounds.
3.5. IBC dose dependently inhibits formation of both OC and A11
positive conformers, whereas BCN generates similar effect on OC
positive conformers but complicated effects on A11 positive
conformers
Ab aggregation is a complicated process involving independent
oligomerization and ﬁbrillization pathways [21,24], although the
two pathways are closely linked by the same dynamic buffer pool
of Ab monomers. To elucidate which pathway of Ab42 aggregation
was modulated by IBC and BCN, we performed dot blot assay using
oligomer-speciﬁc A11 antibody and ﬁbril-speciﬁc OC antibody. OC
antibody recognizes ﬁbrillar intermediates and mature amyloid ﬁ-
brils that are less toxic, ThT-positive and b-sheet-rich structures
[21,23]. When Ab42 was incubated alone, OC positive conformers
accumulated signiﬁcantly as time progressed (Fig. 4). However,
this accumulation was almost completely stopped when either
BCN or IBC was added at a molar ratio of 5:1 (BCN or IBC to
Ab42) and the inhibition by either compound was dose-dependent
(Fig. 4). This demonstrated both compounds inhibited Ab42 ﬁbril-
lization process. In contrast to OC, A11 antibody recognizes soluble
oligomers that are more toxic and ThT-negative [21,24,25]. In
agreement with previous ﬁndings [26], A11-positive conformers
appeared to be transiently present in Ab42 samples during incuba-
tion period, and they were recognized by A11 at day 3 but not day
0 or day 7 of incubation. Addition of IBC signiﬁcantly inhibited A11
blotting signal indicating that IBC also inhibited Ab42 oligomeriza-
tion (Fig. 4). Surprisingly, BCN signiﬁcantly enhanced A11 blotting
signal at all time points at a molar ratio of 1:1 (Fig. 4 1), indicat-
ing that BCN may rapidly promote and further stabilize the forma-
tion of A11-positive oligomers. Even more strikingly, this
enhancing effect diminishes as concentration of BCN increases
(Fig. 4) or decreases (data not shown).
3.6. IBC inhibits both oligomerization and ﬁbrillization of Ab42
whereas BCN promotes oligomerization and off-pathway aggregation
In order to further understand the mechanisms of IBC and BCN
inhibiting Ab42 ﬁbrillization, we performed pellet-ThT ﬂuores-
cence assay and CD spectrum analysis. After 7 days of incubation,
Ab42 alone formed signiﬁcant amount of aggregates that can beFig. 3. SDS–PAGE analysis of Ab42 aggregation. (A) Ab42 samples (50 lM) were incubat
Arrows indicate monomers, trimers/tetramers, and high molecular weight (HMW) aggrepelleted by centrifugation and recognized by ThT indicated by
the increase of ﬂuorescence at 490 nm (Fig. 5A). CD analysis further
revealed that Ab42 at day 7 had a predominant b-structure, as indi-
cated by a minimum at 217 nm in CD spectra (Fig. 5C). However,
addition of either IBC or BCN to Ab42 greatly reduced both ThT-po-
sitive pellets (Fig. 5B) and b-sheet content (Fig. 5C), suggested that
the ‘‘on-pathway’’ aggregation of Ab42 were signiﬁcantly inhibited
by both compounds. Interestingly, majority of Ab42 peptides were
converted to random coil conformers by IBC, as indicated by a
characteristic minimum near 200 nm in CD spectra (Fig. 5C).
We next performed AFM analysis to monitor morphological
changes of Ab42 during the incubation. As shown in Fig. 6A, initial
Ab42 peptides are morphologically heterogeneous and mainly con-
sisted of monomers and small size oligomers. After 7 days of incu-
bation, the peptides assembled into noticeably larger aggregates as
well as a few protoﬁbrils and mature ﬁbrils (Fig. 6A). However,
these ﬁbrillar aggregates were not observed in Ab42 samples trea-
ted with either IBC or BCN, indicating Ab42 ﬁbrillization was sig-
niﬁcantly inhibited (Fig. 6B). Moreover, IBC dose dependently
blocked formation of larger size aggregates and resulted in small
size conformers comparable with the initial Ab42 at a molar ratio
of 5:1 (Fig. 6B, upper panel). This further conﬁrmed IBC as an effec-
tive inhibitor of Ab42 ﬁbrillization and oligomerization. To our sur-
prise, BCN promoted and stabilized formation of small size
conformers at equimolar concentration, but strongly enhanced
Ab42 aggregation at higher concentration and produced much lar-
ger aggregates than Ab42 alone control (Fig. 6B, lower panel).
3.7. Both IBC and BCN attenuate Ab42-induced cell toxicity in SH-SY5Y
cells
To investigate whether IBC and BCN could attenuate Ab42 tox-
icity, we utilized MTT assay to assess cell viability of SH-SY5Yed for 6 h with PFE (200 lg/ml), IBC (5, a molar ratio of 5:1 to Ab42) or BCN (5).
gates. (B) Mean density of the gel bands, n = 3. ⁄⁄P < 0.01 (versus Ab42 alone, 6 h).
Fig. 5. IBC and BCN inhibited Ab42 ﬁbrillization. Ab42 samples (50 lM) were incubated for 7 days with IBC or BCN. (A) ThT ﬂuorescence spectra of the pellet and supernatant
fraction of Ab42 control samples. (B) ThT ﬂuorescence spectra of the pellet fractions of BCN and IBC treated samples. (C) CD spectra of Ab42 alone, IBC treated and BCN treated
samples. Each spectrum is an average of three independent experiments.
Fig. 6. IBC and BCN modiﬁed morphology of Ab42 and attenuated its cell toxicity. Ab42 samples (50 lM) were incubated for 0–7 days with IBC or BCN. The compounds were
added at a molar ratio of 1:1 (1), 2:1 (2) or 5:1 (5). (A) AFM images of Ab42 alone samples at day 0 and day 7. (B) AFM images of IBC- and BCN-treated samples at day 7.
Scale bar = 500 nm. (C) Cell viability analysis by MTT assay of SH-SY5Y cells treated with Ab42 (day 3) or compound alone (upper panel, ⁄⁄P < 0.01 versus DMSO control), and
compound-treated Ab42 samples (lower panel, ⁄P < 0.05, ⁄⁄P < 0.01 versus 1 lM Ab42 alone).
2934 X. Chen et al. / FEBS Letters 587 (2013) 2930–2935human neuroblastoma cells treated with Ab42 samples. We ﬁrst
conﬁrmed that aggregated Ab42 signiﬁcantly reduced SH-SY5Y cell
viability in a dose-dependent manner as shown in Fig. 6C, and both
IBC and BCN showed limited cell toxicity to SH-SY5Y cells at a con-
centration of 1 or 5 lM. However, IBC greatly reduced cell viability
at 25 lM indicative of strong toxic effect (Fig. 6C, upper panell).
Thus the inﬂuences of IBC and BCN on Ab42 toxicity were only ana-
lyzed at 1 and 5 lM corresponding to molar ratios of 1:1 and 5:1 to
Ab42 (1 lM). We found that both of the compounds signiﬁcantly
suppressed Ab42-induced cell toxicity (Fig. 6C, lower panel).
4. Discussion
Small molecular inhibitors can modulate the process of Ab42
aggregation [24] or remodel the conformers of Ab42 aggregates
[21] through different mechanisms. Necula et al., categorized 35
inhibitors into three classes [24]: class I compounds inhibit oligo-
merization without inhibiting ﬁbrillization, class II compounds in-
hibit both, and class III compounds only inhibit ﬁbrillization. In this
study, we identiﬁed two active compounds from Psoraleae Fructus,
IBC and BCN, inhibiting the ‘‘on-pathway’’ aggregation and the cell
toxicity of Ab42 peptides. IBC acts as a class II inhibitor, whereas
BCN might belong to class III, according to Necula’s classiﬁcation
[24].
Similar to the remodeling effects of resveratrol [26], EGCG [27],
myricetin and nordihydroguaiaretic acid (NDGA) [21], BCN modu-
lates Ab42 into large ‘‘off-pathway’’ aggregates at higher concen-tration (molar ratio to Ab42 at 2:1 or 5:1). This could be related
to the hydrophobic property of BCN that enables tight binding to
the hydrophobic core of Ab42. Binding of BCN might also promote
the hydrophobic interaction of Ab42 monomers and oligomers
leading to formation of large insoluble aggregates, as seen in
AFM studies (Fig. 6B). However, these large aggregates are con-
formationally different from the ‘‘on-pathway’’ aggregates of
Ab42 peptides formed in the absence of BCN, since they were not
recognized by ThT, OC or A11 antibody.
Surprisingly, BCN seems to promote the formation of A11-posi-
tive oligomers at an equimolar concentration (molar ratio of 1:1 to
Ab42, Fig. 4). Similar A11-enhancing effect has been reported pre-
viously in resveratrol [28] and NDGA [6] studies. In our study, we
also found that resveratrol enhanced A11 blotting signal while
EGCG inhibited it (data not shown). Since A11-positve oligomers
are believed to be highly toxic, the above ﬁndings might be conﬂict
with their protection effects as seen in Ab42-induced cell toxicity
analyses [26,28,6]. A reasonable explanation could be that these
compounds may simply mediate binding of A11 antibody to
Ab42 conformers rather than modulate Ab42 into A11-positive
oligomers.
In contrast to BCN, IBC inhibited both oligomerization and
ﬁbrillization of Ab42. This may result from its favorable structural
properties as suggested by previous studies. The efﬁcient polyphe-
nol inhibitors are normally composed of at least two phenolic rings
with two to six atom linkers, and a minimum of three hydroxyl
groups on the aromatic rings [7]. Although many plant phenolic
Table 1
In silico prediction of human intestinal absorption and blood–brain barrier penetra-
tion after oral administration of IBC, BCN and selected Ab42 aggregation inhibitors.
Compounds Absorption level BBB level
Baicalein Good Low
Myricetin Very low 
Piceid Moderate 
Rosmarinic acid Low 
Resveratrol Good Medium
EGCG Very low 
Tannic acid Very low 
IBC* Good High
BCN* Good High
‘‘’’: Undeﬁned by Discovery Studio.
* Compounds in this study.
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itors, only a few were reported to inhibit both oligomerization and
ﬁbrillization, such as piceid and tannic acid [21]. Moreover, the
application of these inhibitors for AD therapy was limited by the
low bioavailability due to poor absorption and low blood–brain
barrier (BBB) penetration [29,30]. Compared with known phenolic
inhibitors, the prenylated structures of IBC and BCN are more
hydrophobic, implicating better bioavailability. We therefore pre-
dicted the oral and CNS bioavailability of IBC and BCN in compar-
ison with the most effective phenolic inhibitors reported
elsewhere [7,31], using ADMET descriptors in Discovery Studio
software (Accelrys). Indeed, we found that both IBC and BCN
showed good oral absorption and high BBB penetration in this
model (Table 1). Although IBC can inhibit both oligomerization
and ﬁbrillization of Ab42 in vitro, its cell toxic property is not
favorable for CNS drug development. We are currently trying to
analyze the structure–activity relationship of IBC by investigating
its structural analogs.
In conclusion, the present study demonstrated that IBC and BCN
from Psoraleae Fructusmodulate Ab42 aggregation process through
two different mechanisms. IBC signiﬁcantly inhibits both oligo-
merization and ﬁbrillarization of Ab42, while BCN converts Ab42
into large unstructured aggregates. Both of the compounds can sig-
niﬁcantly suppress Ab42-induced toxicity in SH-SY5Y human neu-
roblastoma cells.
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